Pharmacokinetics and safety of a phenytoin prodrug given IV or IM in patients

I. E. Leppik; B. A. Boucher; B. J. Wilder; V. S. Murthy; C. Watridge; N. M. Graves; R. J. Rangel; C. A. Rask; P. Turlapaty

doi:10.1212/wnl.40.3_part_1.456

Pharmacokinetics and safety of a phenytoin prodrug given IV or IM in patients

I. E. Leppik, B. A. Boucher, B. J. Wilder, V. S. Murthy, C. Watridge, N. M. Graves, R. J. Rangel, C. A. Rask, P. Turlapaty

Experimental and Clinical Pharmacology

Research output: Contribution to journal › Article › peer-review

85 Scopus citations

Abstract

ACC-9653, a prodrug of phenytoin synthesized to be water soluble, is converted to phenytoin by phosphatases. In this study, 43 patients received ACC-9653 IV or IM. Side effects were transient and minor. The conversion half-lives of ACC-9653 after intravenous and intramuscular administration averaged 8.4 and 32.7 minutes, respectively. Peak phenytoin concentrations occurred 42 minutes after IV and 151 minutes after IM administration.

Original language	English (US)
Pages (from-to)	456-460
Number of pages	5
Journal	Neurology
Volume	40
Issue number	3
DOIs	https://doi.org/10.1212/wnl.40.3_part_1.456
State	Published - Mar 1990

Publisher link

10.1212/wnl.40.3_part_1.456

Find It

Find It at U of M Libraries

Cite this

@article{2b424655e7d148eca106b8a52759d759,

title = "Pharmacokinetics and safety of a phenytoin prodrug given IV or IM in patients",

abstract = "ACC-9653, a prodrug of phenytoin synthesized to be water soluble, is converted to phenytoin by phosphatases. In this study, 43 patients received ACC-9653 IV or IM. Side effects were transient and minor. The conversion half-lives of ACC-9653 after intravenous and intramuscular administration averaged 8.4 and 32.7 minutes, respectively. Peak phenytoin concentrations occurred 42 minutes after IV and 151 minutes after IM administration.",

author = "Leppik, {I. E.} and Boucher, {B. A.} and Wilder, {B. J.} and Murthy, {V. S.} and C. Watridge and Graves, {N. M.} and Rangel, {R. J.} and Rask, {C. A.} and P. Turlapaty",

year = "1990",

month = mar,

doi = "10.1212/wnl.40.3_part_1.456",

language = "English (US)",

volume = "40",

pages = "456--460",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

TY - JOUR

T1 - Pharmacokinetics and safety of a phenytoin prodrug given IV or IM in patients

AU - Leppik, I. E.

AU - Boucher, B. A.

AU - Wilder, B. J.

AU - Murthy, V. S.

AU - Watridge, C.

AU - Graves, N. M.

AU - Rangel, R. J.

AU - Rask, C. A.

AU - Turlapaty, P.

PY - 1990/3

Y1 - 1990/3

N2 - ACC-9653, a prodrug of phenytoin synthesized to be water soluble, is converted to phenytoin by phosphatases. In this study, 43 patients received ACC-9653 IV or IM. Side effects were transient and minor. The conversion half-lives of ACC-9653 after intravenous and intramuscular administration averaged 8.4 and 32.7 minutes, respectively. Peak phenytoin concentrations occurred 42 minutes after IV and 151 minutes after IM administration.

AB - ACC-9653, a prodrug of phenytoin synthesized to be water soluble, is converted to phenytoin by phosphatases. In this study, 43 patients received ACC-9653 IV or IM. Side effects were transient and minor. The conversion half-lives of ACC-9653 after intravenous and intramuscular administration averaged 8.4 and 32.7 minutes, respectively. Peak phenytoin concentrations occurred 42 minutes after IV and 151 minutes after IM administration.

UR - http://www.scopus.com/inward/record.url?scp=0025238997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025238997&partnerID=8YFLogxK

U2 - 10.1212/wnl.40.3_part_1.456

DO - 10.1212/wnl.40.3_part_1.456

M3 - Article

C2 - 2314588

AN - SCOPUS:0025238997

SN - 0028-3878

VL - 40

SP - 456

EP - 460

JO - Neurology

JF - Neurology

IS - 3

ER -

Pharmacokinetics and safety of a phenytoin prodrug given IV or IM in patients

Abstract

Publisher link

Find It

Other files and links

Fingerprint

Cite this